RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.944
+0.014 (1.47%)
At close: Jun 26, 2026, 4:00 PM EDT
0.924
-0.020 (-2.14%)
After-hours: Jun 26, 2026, 5:48 PM EDT
RenovoRx Employees
RenovoRx had 17 employees as of December 31, 2025. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$87,588
Profits / Employee
-$721,706
Market Cap
42.56M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 118 |
| INmune Bio | 21 |
| Tevogen Bio Holdings | 18 |
| Lantern Pharma | 16 |
| CervoMed | 15 |
| Actuate Therapeutics | 12 |
| Genenta Science | 9 |
| Hyperion DeFi | 9 |
RNXT News
- 3 days ago - RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 - Transcripts
- 12 days ago - RenovoRx Slides: Investor presentation - Filings
- 16 days ago - RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 23 days ago - RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - GlobeNewsWire
- 4 weeks ago - RenovoRx announces FDA Orphan Drug Designation for oxaliplatin - TheFly
- 4 weeks ago - RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - RenovoRx announces pharmacokinetic data using TAMP platform - TheFly
- 4 weeks ago - RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting - GlobeNewsWire